Dashboard/REGN/DUPIXENT/event

ReadoutTopline Readout

DUPIXENT Pediatric AD Phase 3 Topline

REGN·DUPIXENT·Atopic Dermatitis·

Approved

·NCT05629468

current best date

'27

HALF8 months

Takeaway

Phase 3 efficacy readout for DUPIXENT in atopic dermatitis patients aged 6 months to 5 years. DUPIXENT is currently approved for ages 6+. Watch: EASI-75 response and pruritus NRS reduction vs. placebo.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~100%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

DUPIXENT (dupilumab) is a biologic therapy co-developed by Regeneron and Sanofi that blocks the interleukin-4 receptor alpha (IL-4Rα), shutting down the IL-4 and IL-13 signaling pathways that drive type 2 inflammation — the immune overreaction underlying atopic dermatitis, asthma, chronic sinusitis, and other allergic conditions. It is given by subcutaneous injection every two weeks and is among the most commercially successful biologic drugs of the past decade, approved across atopic dermatitis, asthma, CRS with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, and alopecia areata. Regeneron continues to expand its approved age range and indications in ongoing trials.

Indication

Immunology

Atopic Dermatitis

MeSH · D003876

No primer in glossary yet.

Trial

recruiting

NCT05629468 ↗

Phase 3 Dupilumab in Pediatric AD

Reference data · comparable readouts

How Appr readouts in Immunology have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

0/0

0% in record

Primary endpoint hit

across 0 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

litifilimab

BIIB · CLE

Ph2 · Sep 2022positiveCLASI-A 38% reductionPR

rocatinlimab

KYME · Atopic dermatitis

Ph2 · Aug 2022positiveEASI-75 56% vs 22% pboPR

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

3 peers in Immunology · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
batoclimab	IMVT	mAb	anti-FcRn mAb	CONFERENCE · Apr 26
ORLADEYOberotralstat	BCRX	small molecule	plasma kallikrein inhibitor	CMC · Jun 26
NTLA-2002	NTLA	gene therapy	in vivo CRISPR knockout of KLKB1	ENROLLMENT · Sep 26

Disclosure trail

1 observation · sorted by confidence

Apr 8, 2026·22d agopinned · highest confidence
MED confPR
top claim
H1'27
HALF
“Topline results from the global Phase 3 study of DUPIXENT in pediatric atopic dermatitis (aged 6 months to 5 years) are expected in the first half of 2027.”
conf 82%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.